This page has only limited features, please log in for full access.

Unclaimed
Nima Rezaei
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Review
Published: 24 August 2021 in Journal of Medical Virology
Reads 0
Downloads 0

Coronavirus disease 2019 (COVID-19) is still propagating a year after the start of the pandemic. Besides the complications patients face during the COVID-19 disease period, there is an accumulating body of evidence concerning the late-onset complications of COVID-19, of which autoimmune manifestations have attracted a remarkable attention from the first months of the pandemic. Autoimmune hemolytic anemia, immune thrombocytopenic purpura, autoimmune thyroid diseases, Kawasaki disease, Guillain-Barre syndrome, and the detection of autoantibodies are of the cues to the discovery of the potentials of COVID-19 in inducing autoimmunity. Clarification of the pathophysiology of COVID-19 injuries to the host, whether it is direct viral injury or the autoimmunity, could help to develop an appropriate treatment.

ACS Style

Niloufar Yazdanpanah; Nima Rezaei. Autoimmune Complications of COVID‐19. Journal of Medical Virology 2021, 1 .

AMA Style

Niloufar Yazdanpanah, Nima Rezaei. Autoimmune Complications of COVID‐19. Journal of Medical Virology. 2021; ():1.

Chicago/Turabian Style

Niloufar Yazdanpanah; Nima Rezaei. 2021. "Autoimmune Complications of COVID‐19." Journal of Medical Virology , no. : 1.

Review article
Published: 24 August 2021 in Journal of Neuroimmunology
Reads 0
Downloads 0

Gut microbiota composition may affect the central nervous system (CNS) and immune function. Several studies have recently examined the possible link between gut microbiota composition and multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE). Most of these studies agree that patients with MS suffer from dysbiosis. Moreover, an altered proportion of certain phyla of bacteria was detected in the digestive tracts of these patients compared to healthy individuals. This review article gathers information from research papers that have examined the relationship between gut microbiota composition and MS and its possible mechanisms.

ACS Style

Melina Farshbafnadi; Elmira Agah; Nima Rezaei. The second brain: The connection between gut microbiota composition and multiple sclerosis. Journal of Neuroimmunology 2021, 1 .

AMA Style

Melina Farshbafnadi, Elmira Agah, Nima Rezaei. The second brain: The connection between gut microbiota composition and multiple sclerosis. Journal of Neuroimmunology. 2021; ():1.

Chicago/Turabian Style

Melina Farshbafnadi; Elmira Agah; Nima Rezaei. 2021. "The second brain: The connection between gut microbiota composition and multiple sclerosis." Journal of Neuroimmunology , no. : 1.

Journal article
Published: 19 August 2021 in Clinical Immunology
Reads 0
Downloads 0

Intravenous immunoglobulins (IVIg) are the major treatment in inborn errors of immunity (IEI) disorders; However, IVIg infusions show some adverse effects. We aimed to assess the adverse reactions of IVIg infusions. Data of IVIg infusions in IEI patients were collected from 2011 to 2021. Totally, 363 IEI patients received IVIg regularly in Iran entered the study. The adverse reactions are classified regarding their severity and chronicity. 22,667 IVIg infusions were performed in the study. 157 patients (43.2%) and 1349 (5.9%) infusions were associated with at least one type of adverse reaction. The highest rates of adverse reactions were seen in severe combined immunodeficiency. Myalgia, chills, headache, fever, and hypotension were the most frequent adverse effects of IVIg. The reactions affect almost half of the patients mainly in the first infusions which necessitate the close observation of IEI patients receiving IVIg.

ACS Style

Hossein Esmaeilzadeh; Aida Askarisarvestani; Nazanin Hosseini; Sahar Samimi; Alireza Shafiei; Seyed Alireza Mahdaviani; Narges Eslami; Zahra Chavoshzadeh; Mazdak Fallahi; Nasrin Khakbazanfard; Mahnaz Sadeghi Shabestari; Soheila Aleyasin; Seyed Hesamedin Nabavizadeh; Taher Cheraghi; Arash Kalantari; Akefeh Ahmadiafshar; Mojgan Safari; Mohammad Hossein Eslamian; Rasol Molatefi; Afshin Shirkani; Marzieh Heidarzadeh Arani; Marzieh Tavakol; Mohammad Hassan Bemanian; Saba Arshi; Mohammad Nabavi; Sima Shokri; Babak Shahhosseini; Negar Mortazavi; Pooria Nakhaei; Farzad Nazari; Morteza Fallahpour; Hamid Ahanchian; Nasrin Moazzen; Maryam Khoshkhui; Ahmad Vosughi Motlagh; Asghar Aghamohammadi; Hassan Abolhassani; Reza Yazdani; Nima Rezaei. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin. Clinical Immunology 2021, 230, 108826 .

AMA Style

Hossein Esmaeilzadeh, Aida Askarisarvestani, Nazanin Hosseini, Sahar Samimi, Alireza Shafiei, Seyed Alireza Mahdaviani, Narges Eslami, Zahra Chavoshzadeh, Mazdak Fallahi, Nasrin Khakbazanfard, Mahnaz Sadeghi Shabestari, Soheila Aleyasin, Seyed Hesamedin Nabavizadeh, Taher Cheraghi, Arash Kalantari, Akefeh Ahmadiafshar, Mojgan Safari, Mohammad Hossein Eslamian, Rasol Molatefi, Afshin Shirkani, Marzieh Heidarzadeh Arani, Marzieh Tavakol, Mohammad Hassan Bemanian, Saba Arshi, Mohammad Nabavi, Sima Shokri, Babak Shahhosseini, Negar Mortazavi, Pooria Nakhaei, Farzad Nazari, Morteza Fallahpour, Hamid Ahanchian, Nasrin Moazzen, Maryam Khoshkhui, Ahmad Vosughi Motlagh, Asghar Aghamohammadi, Hassan Abolhassani, Reza Yazdani, Nima Rezaei. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin. Clinical Immunology. 2021; 230 ():108826.

Chicago/Turabian Style

Hossein Esmaeilzadeh; Aida Askarisarvestani; Nazanin Hosseini; Sahar Samimi; Alireza Shafiei; Seyed Alireza Mahdaviani; Narges Eslami; Zahra Chavoshzadeh; Mazdak Fallahi; Nasrin Khakbazanfard; Mahnaz Sadeghi Shabestari; Soheila Aleyasin; Seyed Hesamedin Nabavizadeh; Taher Cheraghi; Arash Kalantari; Akefeh Ahmadiafshar; Mojgan Safari; Mohammad Hossein Eslamian; Rasol Molatefi; Afshin Shirkani; Marzieh Heidarzadeh Arani; Marzieh Tavakol; Mohammad Hassan Bemanian; Saba Arshi; Mohammad Nabavi; Sima Shokri; Babak Shahhosseini; Negar Mortazavi; Pooria Nakhaei; Farzad Nazari; Morteza Fallahpour; Hamid Ahanchian; Nasrin Moazzen; Maryam Khoshkhui; Ahmad Vosughi Motlagh; Asghar Aghamohammadi; Hassan Abolhassani; Reza Yazdani; Nima Rezaei. 2021. "Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin." Clinical Immunology 230, no. : 108826.

Journal article
Published: 16 August 2021 in Current Pharmaceutical Design
Reads 0
Downloads 0

: Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults, causing many deaths each year. The life expectancy of patients from the time of diagnosis does not exceed 15 months. Tumoral cells are generally surrounded by a bed of tumor microenvironment (TME), composed of various components such as different immune cells, stromal cells, and blood vessels. Previous studies on the treatment of this tumor have generally focused on cancerous cells and therefore, have introduced conventional therapies for eradicating this tumor, including maximal safe surgery, chemotherapy with temozolomide (TMZ), and radiotherapy. Despite treatment with this method, tumors almost always recur, and life expectancy has not increased much. Recently, due to the discovery of the various roles of immune cells (including tumor-associated macrophages or TAMs) in the pathogenesis of this disease, the path of studies has moved towards targeting them as a treatment for glioblastoma. In this review, we aimed to investigate recent studies on the different roles of TME components, the role of TAM in the pathogenesis, and novel methods that target TAMs, including induction of TAM repolarization, inhibition of TAM-produced cytokines, and prohibition of immune system suppression induced by TAMs. In this regard, various targets, including colony-stimulating factor-1 (CSF-1) receptors, Nuclear factor-kappa B (NF-κB), or chemokine receptor (CXCR) pathways, are investigated.

ACS Style

Arash Heidari; Pouya Mahdavi Sharif; Nima Rezaei. The association between tumor-associated macrophages and glioblastoma: a potential target for therapy. Current Pharmaceutical Design 2021, 27, 1 -1.

AMA Style

Arash Heidari, Pouya Mahdavi Sharif, Nima Rezaei. The association between tumor-associated macrophages and glioblastoma: a potential target for therapy. Current Pharmaceutical Design. 2021; 27 ():1-1.

Chicago/Turabian Style

Arash Heidari; Pouya Mahdavi Sharif; Nima Rezaei. 2021. "The association between tumor-associated macrophages and glioblastoma: a potential target for therapy." Current Pharmaceutical Design 27, no. : 1-1.

Commentary
Published: 10 August 2021 in Cell Biology International
Reads 0
Downloads 0
ACS Style

Marcarious M. Tantuoyir; Nima Rezaei. Serological tests for COVID‐19: Potential opportunities. Cell Biology International 2021, 1 .

AMA Style

Marcarious M. Tantuoyir, Nima Rezaei. Serological tests for COVID‐19: Potential opportunities. Cell Biology International. 2021; ():1.

Chicago/Turabian Style

Marcarious M. Tantuoyir; Nima Rezaei. 2021. "Serological tests for COVID‐19: Potential opportunities." Cell Biology International , no. : 1.

Review
Published: 03 August 2021 in Pharmaceutics
Reads 0
Downloads 0

The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the malignant transformation, growth, proliferation, and metastasis of various cancers and solid tumors. Relevant connections between the PI3K/Akt/mTOR pathway, cell survival, and prostate cancer (PC) provide a great therapeutic target for PC prevention or treatment. Recent studies have focused on small-molecule mTOR inhibitors or their usage in coordination with other therapeutics for PC treatment that are currently undergoing clinical testing. In this study, the function of the PI3K/Akt/mTOR pathway, the consequence of its dysregulation, and the development of mTOR inhibitors, either as an individual substance or in combination with other agents, and their clinical implications are discussed. The rationale for targeting the PI3K/Akt/mTOR pathway, and specifically the application and potential utility of natural agents involved in PC treatment is described. In addition to the small-molecule mTOR inhibitors, there are evidence that several natural agents are able to target the PI3K/Akt/mTOR pathway in prostatic neoplasms. These natural mTOR inhibitors can interfere with the PI3K/Akt/mTOR pathway through multiple mechanisms; however, inhibition of Akt and suppression of mTOR 1 activity are two major therapeutic approaches. Combination therapy improves the efficacy of these inhibitors to either suppress the PC progression or circumvent the resistance by cancer cells.

ACS Style

Nazanin Roudsari; Naser-Aldin Lashgari; Saeideh Momtaz; Shaghayegh Abaft; Fatemeh Jamali; Pardis Safaiepour; Kiyana Narimisa; Gloria Jackson; Anusha Bishayee; Nima Rezaei; Amir Abdolghaffari; Anupam Bishayee. Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention. Pharmaceutics 2021, 13, 1195 .

AMA Style

Nazanin Roudsari, Naser-Aldin Lashgari, Saeideh Momtaz, Shaghayegh Abaft, Fatemeh Jamali, Pardis Safaiepour, Kiyana Narimisa, Gloria Jackson, Anusha Bishayee, Nima Rezaei, Amir Abdolghaffari, Anupam Bishayee. Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention. Pharmaceutics. 2021; 13 (8):1195.

Chicago/Turabian Style

Nazanin Roudsari; Naser-Aldin Lashgari; Saeideh Momtaz; Shaghayegh Abaft; Fatemeh Jamali; Pardis Safaiepour; Kiyana Narimisa; Gloria Jackson; Anusha Bishayee; Nima Rezaei; Amir Abdolghaffari; Anupam Bishayee. 2021. "Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention." Pharmaceutics 13, no. 8: 1195.

Journal article
Published: 26 July 2021 in Expert Opinion on Pharmacotherapy
Reads 0
Downloads 0

Neuroblastoma is the most prevalent cancer type diagnosed within the first year after birth and accounts for 15% of deaths from pediatric cancer. Despite the improvements in survival rates of patients with neuroblastoma, the incidence of the disease has increased over the last decade. Neuroblastoma tumor cells harbor a vast range of variable and heterogeneous histochemical and genetic alterations which calls for the need to administer individualized and targeted therapies to induce tumor regression in each patient. This paper provides reviews the recent clinical trials which used chemotherapeutic and/or targeted agents as either monotherapies or in combination to improve the response rate in patients with neuroblastoma, and especially high-risk neuroblastoma. It also reviews some of the prominent preclinical studies which can provide the rationale for future clinical trials. Although some distinguished advances in pharmacotherapy have been made to improve the survival rate and reduce adverse events in patients with neuroblastoma, a more comprehensive understanding of the mechanisms of tumorigenesis, resistance to therapies or relapse, identifying biomarkers of response to each specific drug, and developing predictive preclinical models of the tumor can lead to further breakthroughs in the treatment of neuroblastoma.

ACS Style

Parmida Sadat Pezeshki; Aysan Moeinafshar; Faezeh Ghaemdoust; Sepideh Razi; Mahsa Keshavarz-Fathi; Nima Rezaei. Advances in pharmacotherapy for neuroblastoma. Expert Opinion on Pharmacotherapy 2021, 1 -22.

AMA Style

Parmida Sadat Pezeshki, Aysan Moeinafshar, Faezeh Ghaemdoust, Sepideh Razi, Mahsa Keshavarz-Fathi, Nima Rezaei. Advances in pharmacotherapy for neuroblastoma. Expert Opinion on Pharmacotherapy. 2021; ():1-22.

Chicago/Turabian Style

Parmida Sadat Pezeshki; Aysan Moeinafshar; Faezeh Ghaemdoust; Sepideh Razi; Mahsa Keshavarz-Fathi; Nima Rezaei. 2021. "Advances in pharmacotherapy for neuroblastoma." Expert Opinion on Pharmacotherapy , no. : 1-22.

Review
Published: 14 July 2021 in Clinical Immunology
Reads 0
Downloads 0

Inherited phagocyte defects are one of the subgroups of primary immunodeficiency diseases (PIDs) with various clinical manifestations. As oral manifestations are common at the early ages, oral practitioners can have a special role in the early diagnosis. A comprehensive search was conducted in this systematic review study and data of included studies were categorized into four subgroups of phagocyte defects, including congenital neutropenia, defects of motility, defects of respiratory burst, and other non-lymphoid defects. Among all phagocyte defects, 12 disorders had reported data for oral manifestations in published articles. A total of 987 cases were included in this study. Periodontitis is one of the most common oral manifestations. There is a need to organize better collaboration between medical doctors and dentists to diagnose and treat patients with phagocyte defects. Regular dental visits and professional oral health care are recommended from the time of the first primary teeth eruption in newborns.

ACS Style

Heliya Ziaei; Arghavan Tonkaboni; Ahmadreza Shamshiri; Nima Rezaei. “Oral Manifestations of Patients with Inherited Defect in Phagocyte Number or Function” a systematic review. Clinical Immunology 2021, 229, 108796 .

AMA Style

Heliya Ziaei, Arghavan Tonkaboni, Ahmadreza Shamshiri, Nima Rezaei. “Oral Manifestations of Patients with Inherited Defect in Phagocyte Number or Function” a systematic review. Clinical Immunology. 2021; 229 ():108796.

Chicago/Turabian Style

Heliya Ziaei; Arghavan Tonkaboni; Ahmadreza Shamshiri; Nima Rezaei. 2021. "“Oral Manifestations of Patients with Inherited Defect in Phagocyte Number or Function” a systematic review." Clinical Immunology 229, no. : 108796.

Opinion
Published: 13 July 2021 in Biomolecules
Reads 0
Downloads 0

Two adenovirus-based vaccines, ChAdOx1 nCoV-19 and Ad26.COV2.S, and two mRNA-based vaccines, BNT162b2 and mRNA.1273, have been approved by the European Medicines Agency (EMA), and are invaluable in preventing and reducing the incidence of coronavirus disease-2019 (COVID-19). Recent reports have pointed to thrombosis with associated thrombocytopenia as an adverse effect occurring at a low frequency in some individuals after vaccination. The causes of such events may be related to SARS-CoV-2 spike protein interactions with different C-type lectin receptors, heparan sulfate proteoglycans (HSPGs) and the CD147 receptor, or to different soluble splice variants of the spike protein, adenovirus vector interactions with the CD46 receptor or platelet factor 4 antibodies. Similar findings have been reported for several viral diseases after vaccine administration. In addition, immunological mechanisms elicited by viral vectors related to cellular delivery could play a relevant role in individuals with certain genetic backgrounds. Although rare, the potential COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) requires immediate validation, especially in risk groups, such as the elderly, chronic smokers, and individuals with pre-existing incidences of thrombocytopenia; and if necessary, a reformulation of existing vaccines.

ACS Style

Kenneth Lundstrom; Debmalya Barh; Bruce Uhal; Kazuo Takayama; Alaa Aljabali; Tarek Abd El-Aziz; Amos Lal; ElRashdy Redwan; Parise Adadi; Gaurav Chauhan; Samendra Sherchan; Gajendra Azad; Nima Rezaei; Ángel Serrano-Aroca; Nicolas Bazan; Sk Hassan; Pritam Panda; Pabitra Pal Choudhury; Damiano Pizzol; Ramesh Kandimalla; Wagner Baetas-Da-Cruz; Yogendra Mishra; Giorgio Palu; Adam Brufsky; Murtaza Tambuwala; Vladimir Uversky. COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street? Biomolecules 2021, 11, 1020 .

AMA Style

Kenneth Lundstrom, Debmalya Barh, Bruce Uhal, Kazuo Takayama, Alaa Aljabali, Tarek Abd El-Aziz, Amos Lal, ElRashdy Redwan, Parise Adadi, Gaurav Chauhan, Samendra Sherchan, Gajendra Azad, Nima Rezaei, Ángel Serrano-Aroca, Nicolas Bazan, Sk Hassan, Pritam Panda, Pabitra Pal Choudhury, Damiano Pizzol, Ramesh Kandimalla, Wagner Baetas-Da-Cruz, Yogendra Mishra, Giorgio Palu, Adam Brufsky, Murtaza Tambuwala, Vladimir Uversky. COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street? Biomolecules. 2021; 11 (7):1020.

Chicago/Turabian Style

Kenneth Lundstrom; Debmalya Barh; Bruce Uhal; Kazuo Takayama; Alaa Aljabali; Tarek Abd El-Aziz; Amos Lal; ElRashdy Redwan; Parise Adadi; Gaurav Chauhan; Samendra Sherchan; Gajendra Azad; Nima Rezaei; Ángel Serrano-Aroca; Nicolas Bazan; Sk Hassan; Pritam Panda; Pabitra Pal Choudhury; Damiano Pizzol; Ramesh Kandimalla; Wagner Baetas-Da-Cruz; Yogendra Mishra; Giorgio Palu; Adam Brufsky; Murtaza Tambuwala; Vladimir Uversky. 2021. "COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?" Biomolecules 11, no. 7: 1020.

Review article
Published: 12 July 2021 in Frontiers in Oncology
Reads 0
Downloads 0

Glioma is the most common malignant central nervous system tumor with significant mortality and morbidity. Despite considerable advances, the exact molecular pathways involved in tumor progression are not fully elucidated, and patients commonly face a poor prognosis. Long non-coding RNAs (lncRNAs) have recently drawn extra attention for their potential roles in different types of cancer as well as non-malignant diseases. More than 200 lncRNAs have been reported to be associated with glioma. We aimed to assess the roles of the most investigated lncRNAs in different stages of tumor progression and the mediating molecular pathways in addition to their clinical applications. lncRNAs are involved in different stages of tumor formation, invasion, and progression, including regulating the cell cycle, apoptosis, autophagy, epithelial-to-mesenchymal transition, tumor stemness, angiogenesis, the integrity of the blood-tumor-brain barrier, tumor metabolism, and immunological responses. The well-known oncogenic lncRNAs, which are upregulated in glioma, are H19, HOTAIR, PVT1, UCA1, XIST, CRNDE, FOXD2-AS1, ANRIL, HOXA11-AS, TP73-AS1, and DANCR. On the other hand, MEG3, GAS5, CCASC2, and TUSC7 are tumor suppressor lncRNAs, which are downregulated. While most studies reported oncogenic effects for MALAT1, TUG1, and NEAT1, there are some controversies regarding these lncRNAs. Expression levels of lncRNAs can be associated with tumor grade, survival, treatment response (chemotherapy drugs or radiotherapy), and overall prognosis. Moreover, circulatory levels of lncRNAs, such as MALAT1, H19, HOTAIR, NEAT1, TUG1, GAS5, LINK-A, and TUSC7, can provide non-invasive diagnostic and prognostic tools. Modulation of expression of lncRNAs using antisense oligonucleotides can lead to novel therapeutics. Notably, a profound understanding of the underlying molecular pathways involved in the function of lncRNAs is required to develop novel therapeutic targets. More investigations with large sample sizes and increased focus on in-vivo models are required to expand our understanding of the potential roles and application of lncRNAs in glioma.

ACS Style

Sara Momtazmanesh; Nima Rezaei. Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review. Frontiers in Oncology 2021, 11, 1 .

AMA Style

Sara Momtazmanesh, Nima Rezaei. Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review. Frontiers in Oncology. 2021; 11 ():1.

Chicago/Turabian Style

Sara Momtazmanesh; Nima Rezaei. 2021. "Long Non-Coding RNAs in Diagnosis, Treatment, Prognosis, and Progression of Glioma: A State-of-the-Art Review." Frontiers in Oncology 11, no. : 1.

Review article
Published: 03 July 2021 in Biomedicine & Pharmacotherapy
Reads 0
Downloads 0

Cancer stands as one of the most leading causes of death worldwide, while one of the most significant challenges in treating it is revealing novel alternatives to predict, diagnose, and eradicate tumor cell growth. Although various methods, such as surgery, chemotherapy, and radiation therapy, are used today to treat cancer, its mortality rate is still high due to the numerous shortcomings of each approach. Regenerative medicine field, including tissue engineering, cell therapy, gene therapy, participate in cancer treatment and development of cancer models to improve the understanding of cancer biology. The final intention is to convey fundamental and laboratory research to effective clinical treatments, from the bench to the bedside. Proper interpretation of research attempts helps to lessen the burden of treatment and illness for patients. The purpose of this review is to investigate the role of regenerative medicine in accelerating and improving cancer treatment. This study examines the capabilities of regenerative medicine in providing novel cancer treatments and the effectiveness of these treatments to clarify this path as much as possible and promote advanced future research in this field.

ACS Style

Vahid Mansouri; Nima Beheshtizadeh; Maliheh Gharibshahian; Leila Sabouri; Mohammad Varzandeh; Nima Rezaei. Recent advances in regenerative medicine strategies for cancer treatment. Biomedicine & Pharmacotherapy 2021, 141, 111875 .

AMA Style

Vahid Mansouri, Nima Beheshtizadeh, Maliheh Gharibshahian, Leila Sabouri, Mohammad Varzandeh, Nima Rezaei. Recent advances in regenerative medicine strategies for cancer treatment. Biomedicine & Pharmacotherapy. 2021; 141 ():111875.

Chicago/Turabian Style

Vahid Mansouri; Nima Beheshtizadeh; Maliheh Gharibshahian; Leila Sabouri; Mohammad Varzandeh; Nima Rezaei. 2021. "Recent advances in regenerative medicine strategies for cancer treatment." Biomedicine & Pharmacotherapy 141, no. : 111875.

Journal article
Published: 01 July 2021 in Allergologia et Immunopathologia
Reads 0
Downloads 0

Introduction and objectives: Severe combined immunodeficiency (SCID) is a subset of primary immunodeficiency diseases caused by a hereditary deficiency of the adaptive immune system. Mutation in recombination activating gene (RAG) is known as the underlying genetic cause of SCID. RAG protein plays a pivotal role in V(D)J recombination which is the main process to assemble lymphocyte antigen receptors during T- and B-cell development. The patients are characterized by recurrent infections, failure to thrive, chronic diarrhea, and fever, in early infancy. Herein, we present a case of SCID with rare neurological manifestations affected by a mutation in RAG1.Patients and methods: The patient was a 15-month-old infant born to a consanguineous family. She was presented with neurological abnormalities including facial nerve palsy, seizure, and decreased consciousness. Next-generation sequencing (NGS)-based primary immunodeficiency disease (PID)-gene panel screen and Sanger sequencing were performed to identify the genetic mutation.Results: We found a novel homozygous missense mutation in RAG1, c.1210C>T,p.Arg404Trp, which was predicted to be deleterious (combined annotation dependent depletion, CADD score of 27.4). Both parents were heterozygous carriers for this mutation. According to her laboratory data, both T cell and B cell numbers were decreased and the patient was diagnosed as RAG1- SCID.Conclusions: SCID is a pediatric emergency with a variety of manifestations in infants. Therefore, accurate diagnosis importantly in the case of rare manifestations must be considered in these patients. Our findings point toward the importance of genetic assessment for early diagnosis and timely treatment of this disorder.

ACS Style

Melika Shafeghat; Hossein Esmaeilzadeh; Mona Sadeghalvad; Elham Rayzan; Samaneh Zoghi; Sepideh Shahkarami; Raul Jimenez Heredia; Ana Krolo; Kaan Boztug; Nima Rezaei. A novel homozygous RAG1 mutation is associated with severe combined immunodeficiency and neurological presentations. Allergologia et Immunopathologia 2021, 49, 91 -97.

AMA Style

Melika Shafeghat, Hossein Esmaeilzadeh, Mona Sadeghalvad, Elham Rayzan, Samaneh Zoghi, Sepideh Shahkarami, Raul Jimenez Heredia, Ana Krolo, Kaan Boztug, Nima Rezaei. A novel homozygous RAG1 mutation is associated with severe combined immunodeficiency and neurological presentations. Allergologia et Immunopathologia. 2021; 49 (4):91-97.

Chicago/Turabian Style

Melika Shafeghat; Hossein Esmaeilzadeh; Mona Sadeghalvad; Elham Rayzan; Samaneh Zoghi; Sepideh Shahkarami; Raul Jimenez Heredia; Ana Krolo; Kaan Boztug; Nima Rezaei. 2021. "A novel homozygous RAG1 mutation is associated with severe combined immunodeficiency and neurological presentations." Allergologia et Immunopathologia 49, no. 4: 91-97.

Journal article
Published: 01 July 2021 in Acta bio-medica : Atenei Parmensis
Reads 0
Downloads 0

Asthma is a chronic inflammatory disease of airways which accounts for a huge economic, morbidity and mortality burden. There are different cytokines that contribute to asthma pathophysiology. Learning about these cytokines leads to attaining novel anti-inflammatory treatments for asthma control. The objective of this study is to investigate the association between interleukin-9 serum level and gene polymorphism with asthma susceptibility. This was a case-control study of 70 asthmatic patients and 77 healthy control adults aged 18-60. Asthma diagnosis and severity were based on physician diagnosis, pulmonary function test (PFT) and 2016 guild line of Global Initiative for Asthma (GINA). Interleukin 9(IL -9) serum level was measured using sandwich enzyme linked immunosorbent assay. IL9 promoter single nucleotide polymorphism (SNP) (rs2069882) was also assessed using Real-Time PCR System. There was no significant association between IL-9 SNP polymorphism and asthma. IL-9 serum level was significantly associated with asthma susceptibility (p value= 0.016) and absolute eosinophil count (AEC) (P value=0.033) however its corelation with atopic asthma type, asthma sivierity and Immunoglubin E serum level were not statistically significant. Although there was no association between IL-9 SNP and asthma, but IL-9 serum level was significantly correlated with asthma susceptibility and AEC.

ACS Style

Seyed Alireza Mahdaviani; Mahsa Eskian; MirHojjat Khorasanizadeh; Bahram Bashardoost; Sabereh Tashayoie Nejad; Hamid Reza Jamaati; Nima Rezaei. Interleukin 9 serum level and single nucleotide polymorphism in patients with asthma. Acta bio-medica : Atenei Parmensis 2021, 92, e2021206 .

AMA Style

Seyed Alireza Mahdaviani, Mahsa Eskian, MirHojjat Khorasanizadeh, Bahram Bashardoost, Sabereh Tashayoie Nejad, Hamid Reza Jamaati, Nima Rezaei. Interleukin 9 serum level and single nucleotide polymorphism in patients with asthma. Acta bio-medica : Atenei Parmensis. 2021; 92 (3):e2021206.

Chicago/Turabian Style

Seyed Alireza Mahdaviani; Mahsa Eskian; MirHojjat Khorasanizadeh; Bahram Bashardoost; Sabereh Tashayoie Nejad; Hamid Reza Jamaati; Nima Rezaei. 2021. "Interleukin 9 serum level and single nucleotide polymorphism in patients with asthma." Acta bio-medica : Atenei Parmensis 92, no. 3: e2021206.

Review article
Published: 30 June 2021 in Journal of Neuroimmunology
Reads 0
Downloads 0

Guillain-Barré syndrome (GBS) is an autoimmune disease in which the peripheral nerves are affected. GBS has different subtypes, such as acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN). Infections, e.g. Campylobacter jejuni, influenza, etc., can lead to GBS. Both environmental and genetic factors play a major role in the occurrence of GBS. Several studies have investigated the genetic basis of GBS. Human leukocyte antigens (HLA) genes, Cluster of Differentiation (CD) 1A, FAS, Fc gamma receptors (FcGR), Intercellular adhesion molecule-1 (ICAM1), different interleukins, Nucleotide oligomerization domain (NOD), Toll-like receptor 4 (TLR4), Tumor necrosis factor-α (TNF-α) are among the genes reported to be involved in susceptibility to the disease. Dysregulation and dysfunction of the mentioned gene products, even though their role in the pathogenesis of GBS is controversial, play a role in inflammatory pathways, regulation of immune cells and system, antigen presentation, axonal degeneration, apoptosis, and cross-reaction. This review aims to summarize associated genes with GBS to contribute to better understanding of GBS pathogenesis and discover the gene pathways that play role in GBS occurrence.

ACS Style

Shaghayegh Khanmohammadi; Mahdi Malekpour; Parnian Jabbari; Nima Rezaei. Genetic basis of Guillain-Barre syndrome. Journal of Neuroimmunology 2021, 358, 1 .

AMA Style

Shaghayegh Khanmohammadi, Mahdi Malekpour, Parnian Jabbari, Nima Rezaei. Genetic basis of Guillain-Barre syndrome. Journal of Neuroimmunology. 2021; 358 ():1.

Chicago/Turabian Style

Shaghayegh Khanmohammadi; Mahdi Malekpour; Parnian Jabbari; Nima Rezaei. 2021. "Genetic basis of Guillain-Barre syndrome." Journal of Neuroimmunology 358, no. : 1.

Review
Published: 23 June 2021 in Clinical and Translational Oncology
Reads 0
Downloads 0

Acute myeloid leukemia (AML), the most common form of leukemia amongst adults, is one of the most important hematological malignancies. Epidemiological data show both high incidence rates and low survival rates, especially in secondary cases among adults. Although classic and novel chemotherapeutic approaches have extensively improved disease prognosis and survival, the need for more personalized and target-specific methods with less side effects have been inevitable. Therefore, immunotherapeutic methods are of importance. In the following review, primarily a brief understanding of the molecular basis of the disease has been represented. Second, prior to the introduction of immunotherapeutic approaches, the entangled relationship of AML and patient’s immune system has been discussed. At last, mechanistic and clinical evidence of each of the immunotherapy approaches have been covered.

ACS Style

A. Moeinafshar; S. Hemmati; N. Rezaei. Immunotherapy in AML: a brief review on emerging strategies. Clinical and Translational Oncology 2021, 1 -17.

AMA Style

A. Moeinafshar, S. Hemmati, N. Rezaei. Immunotherapy in AML: a brief review on emerging strategies. Clinical and Translational Oncology. 2021; ():1-17.

Chicago/Turabian Style

A. Moeinafshar; S. Hemmati; N. Rezaei. 2021. "Immunotherapy in AML: a brief review on emerging strategies." Clinical and Translational Oncology , no. : 1-17.

Chapter
Published: 17 June 2021 in Integrated Science
Reads 0
Downloads 0

In considering the changing world, the authors of the Integrated Science: Science without Borders were asked how you would see the future of your field 30 years later. The present chapter publishes authors’ views on this subject in 2050. Authors have integrated science into the person, thinking of complex problems, artificial intelligence, management under changing conditions, and a sustainable future. Open image in new window The light integrated science can throw on our thinking of complex problems [Adapted with permission from the Association of Science and Art (ASA), USERN; Made by Nastaran Hosseini]. Open image in new window The puzzle of the Integrated Science: Science Without Borders.

ACS Style

Amene Saghazadeh; Adela Acitores Suz; Antonia Viu; Chih-Fu Wu; Christopher Ryan Maboloc; Dustin Hellberg; Ewa Rzechowska; Henrik Thorén; Henry H. Bauer; Jan Kłos; Jan Treur; Jean-Yves LeCorre; Karolina Żyniewicz; Laura De Miguel Álvarez; Leonardo G. Rodríguez Zoya; Marion Neukam; Monika Michałowska; Ortwin Renn; Rory Allen; Pedro E. Moscoso-Flores; Raúl Díaz-Obregón Cruzado; Silvia Nuere; Sophie Bollinger; Thierry Burger-Helmchen; Thomas Görnitz; Tilia Stingl De Vasconcelos Guedes; Xiao Dou; Žilvinas Svigaris; Nima Rezaei. Integrated Science 2050: Science Without Borders. Integrated Science 2021, 461 -478.

AMA Style

Amene Saghazadeh, Adela Acitores Suz, Antonia Viu, Chih-Fu Wu, Christopher Ryan Maboloc, Dustin Hellberg, Ewa Rzechowska, Henrik Thorén, Henry H. Bauer, Jan Kłos, Jan Treur, Jean-Yves LeCorre, Karolina Żyniewicz, Laura De Miguel Álvarez, Leonardo G. Rodríguez Zoya, Marion Neukam, Monika Michałowska, Ortwin Renn, Rory Allen, Pedro E. Moscoso-Flores, Raúl Díaz-Obregón Cruzado, Silvia Nuere, Sophie Bollinger, Thierry Burger-Helmchen, Thomas Görnitz, Tilia Stingl De Vasconcelos Guedes, Xiao Dou, Žilvinas Svigaris, Nima Rezaei. Integrated Science 2050: Science Without Borders. Integrated Science. 2021; ():461-478.

Chicago/Turabian Style

Amene Saghazadeh; Adela Acitores Suz; Antonia Viu; Chih-Fu Wu; Christopher Ryan Maboloc; Dustin Hellberg; Ewa Rzechowska; Henrik Thorén; Henry H. Bauer; Jan Kłos; Jan Treur; Jean-Yves LeCorre; Karolina Żyniewicz; Laura De Miguel Álvarez; Leonardo G. Rodríguez Zoya; Marion Neukam; Monika Michałowska; Ortwin Renn; Rory Allen; Pedro E. Moscoso-Flores; Raúl Díaz-Obregón Cruzado; Silvia Nuere; Sophie Bollinger; Thierry Burger-Helmchen; Thomas Görnitz; Tilia Stingl De Vasconcelos Guedes; Xiao Dou; Žilvinas Svigaris; Nima Rezaei. 2021. "Integrated Science 2050: Science Without Borders." Integrated Science , no. : 461-478.

Chapter
Published: 17 June 2021 in Integrated Science
Reads 0
Downloads 0

Integrated science [Adapted with permission from the Association of Science and Art (ASA), USERN; Made by Sepideh Sargoli, Shaghayegh Khodabakhshian, and Mahsa Yousefpour]. The code of this chapter is 01000011 01110100 01101111 01101110 01101110 01101110 01100011 01101001 01100101 01101111.

ACS Style

Nima Rezaei; Amene Saghazadeh. Introduction on Integrated Science: Science Without Borders. Integrated Science 2021, 1 -37.

AMA Style

Nima Rezaei, Amene Saghazadeh. Introduction on Integrated Science: Science Without Borders. Integrated Science. 2021; ():1-37.

Chicago/Turabian Style

Nima Rezaei; Amene Saghazadeh. 2021. "Introduction on Integrated Science: Science Without Borders." Integrated Science , no. : 1-37.

Review article
Published: 17 June 2021 in International Immunopharmacology
Reads 0
Downloads 0

Breast cancer is the most common cancer type in women worldwide. Triple-negative breast cancer (TNBC), which is characterized by the absence of estrogen receptor/progesterone receptor (ER/PR) and human epidermal growth factor receptor 2 (Her2) expressions, has a poorer prognosis compared with non-TNBC breast tumors. Until recently systemic treatment for TNBC was confined to chemotherapy owing to the lack of actionable targets. Immune checkpoint molecules are expressed on malignant cells or tumor-infiltrating immune cells and can inhibit anti-cancer immune responses. Immune checkpoint inhibitors (ICI), including anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1), and anti-programmed cell death 1 ligand 1 (PD-L1), induce immune responses in different types of neoplasms. They have recently gained attention for their possible role in TNBC treatment. Several clinical trials have been conducted on the role of immune checkpoint blockade in different settings for TNBC treatment. Available evidence justifies the application of ICI and chemotherapy combination in the management of metastatic TNBC and early-stage TNBC in neoadjuvant setting. This study aims to provide information on the mechanisms of action of ICIs, review the efficacy results of clinical trials using ICIs for TNBC treatment, and assess the side effects of such drugs.

ACS Style

Melina Farshbafnadi; Amin Pastaki Khoshbin; Nima Rezaei. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. International Immunopharmacology 2021, 98, 107876 .

AMA Style

Melina Farshbafnadi, Amin Pastaki Khoshbin, Nima Rezaei. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. International Immunopharmacology. 2021; 98 ():107876.

Chicago/Turabian Style

Melina Farshbafnadi; Amin Pastaki Khoshbin; Nima Rezaei. 2021. "Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence." International Immunopharmacology 98, no. : 107876.

Primary research
Published: 14 June 2021 in Cancer Cell International
Reads 0
Downloads 0

Background Circular RNAs (circRNAs) have been implicated in the initiation and development of breast cancer as functional non-coding RNAs (ncRNA). The roles of circRNAs as the competing endogenous RNAs (ceRNAs) to sponge microRNAs (miRNAs) have also been indicated. However, the functions of circRNAs in breast cancer have not been totally elucidated. This study aimed to explore the clinical implications and possible roles of circ_0044234 in carcinogenesis of the most problematic BC subtype, triple negative breast cancer (TNBC), which are in desperate need of biomarkers and targeted therapies. Methods The importance of circ_0044234 as one of the most dysregulated circRNAs in TNBC was discovered through microarray expression profile analysis. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to confirm the downregulation of circ_0044234 in triple negative tumors and cell lines versus non-triple negative ones. The bioinformatics prediction revealed that circ_0044234 could act as an upstream sponge in the miR-135b/GATA3 axis, two of the most dysregulated transcripts in TNBC. Results Our experimental investigation of circ_0044234 expressions in various BC subtypes as well as cell lines reveals that TNBC expresses circ_0044234 at a substantially lower level than non-TNBC. The ROC curve analysis indicates that it could be applied as a discriminative biomarker to identify TNBC from other BC subtypes. Moreover, circ_0044234 expression could be an independent prognostic biomarker in BC. Interestingly, a substantial inverse expression correlation was detected between circ_0044234 and miR-135b-5p as well as between miR-135b-5p and GATA3 in breast tumors. Conclusions The possible clinical usefulness of circ_0044234 as a promising distinct biomarker and upcoming therapeutic target for TNBC have been indicated in this research. Our comprehensive approach revealed the potential circ_0044234/miR135b-5p/GATA3 ceRNA axis in TNBC.

ACS Style

Farzaneh Darbeheshti; Elham Zokaei; Yaser Mansoori; Sima Emadi Allahyari; Zeeba Kamaliyan; Sepideh Kadkhoda; Javad Tavakkoly Bazzaz; Nima Rezaei; Abbas Shakoori. Circular RNA hsa_circ_0044234 as distinct molecular signature of triple negative breast cancer: a potential regulator of GATA3. Cancer Cell International 2021, 21, 1 -12.

AMA Style

Farzaneh Darbeheshti, Elham Zokaei, Yaser Mansoori, Sima Emadi Allahyari, Zeeba Kamaliyan, Sepideh Kadkhoda, Javad Tavakkoly Bazzaz, Nima Rezaei, Abbas Shakoori. Circular RNA hsa_circ_0044234 as distinct molecular signature of triple negative breast cancer: a potential regulator of GATA3. Cancer Cell International. 2021; 21 (1):1-12.

Chicago/Turabian Style

Farzaneh Darbeheshti; Elham Zokaei; Yaser Mansoori; Sima Emadi Allahyari; Zeeba Kamaliyan; Sepideh Kadkhoda; Javad Tavakkoly Bazzaz; Nima Rezaei; Abbas Shakoori. 2021. "Circular RNA hsa_circ_0044234 as distinct molecular signature of triple negative breast cancer: a potential regulator of GATA3." Cancer Cell International 21, no. 1: 1-12.

Review
Published: 12 June 2021 in European Journal of Pharmacology
Reads 0
Downloads 0

Concern regarding coronavirus (CoV) outbreaks has stayed relevant to global health in the last decades. Emerging COVID-19 infection, caused by the novel SARS-CoV2, is now a pandemic, bringing a substantial burden to human health. Interferon (IFN), combined with other antivirals and various treatments, has been used to treat and prevent MERS-CoV, SARS-CoV, and SARS-CoV2 infections. We aimed to assess the clinical efficacy of IFN-based treatments and combinational therapy with antivirals, corticosteroids, traditional medicine, and other treatments. Major healthcare databases and grey literature were investigated. A three-stage screening was utilized, and included studies were checked against the protocol eligibility criteria. Risk of bias assessment and data extraction were performed, followed by narrative data synthesis. Fifty-five distinct studies of SARS-CoV2, MERS-CoV, and SARS-CoV were spotted. Our narrative synthesis showed a possible benefit in the use of IFN. A good quality cohort showed lower CRP levels in Arbidol (ARB) + IFN group vs. IFN only group. Another study reported a significantly shorter chest X-ray (CXR) resolution in IFN-Alfacon-1 + corticosteroid group compared with the corticosteroid only group in SARS-CoV patients. In a COVID-19 trial, total adverse drug events (ADEs) were much lower in the Favipiravir (FPV) + IFN-α group compared with the LPV/RTV arm (P = 0.001). Also, nausea in patients receiving FPV + IFN-α regimen was significantly lower (P = 0.03). Quantitative analysis of mortality did not show a conclusive effect for IFN/RBV treatment in six moderately heterogeneous MERS-CoV studies (log OR = −0.05, 95% CI: (−0.71,0.62), I2 = 44.71%). A meta-analysis of three COVID-19 studies did not show a conclusive nor meaningful relation between receiving IFN and COVID-19 severity (log OR = −0.44, 95% CI: (−1.13,0.25), I2 = 31.42%). A lack of high-quality cohorts and controlled trials was observed. Evidence suggests the potential efficacy of several combination IFN therapies such as lower ADEs, quicker resolution of CXR, or a decrease in inflammatory cytokines; Still, these options must possibly be further explored before being recommended in public guidelines. For all major CoVs, our results may indicate a lack of a definitive effect of IFN treatment on mortality. We recommend such therapeutics be administered with extreme caution until further investigation uncovers high-quality evidence in favor of IFN or combination therapy with IFN.

ACS Style

Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei. Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies. European Journal of Pharmacology 2021, 906, 174248 .

AMA Style

Kiarash Saleki, Shakila Yaribash, Mohammad Banazadeh, Ehsan Hajihosseinlou, Mahdi Gouravani, Amene Saghazadeh, Nima Rezaei. Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies. European Journal of Pharmacology. 2021; 906 ():174248.

Chicago/Turabian Style

Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei. 2021. "Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies." European Journal of Pharmacology 906, no. : 174248.